title: No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.
abstract: Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy. We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor leads to decay of this reservoir. Nineteen treatment-naive patients initiated this regimen; 9 experienced virologic suppression and continued enfuvirtide-containing therapy for at least 48 weeks. In enfuvirtide-treated patients with virological suppression, there was no decay of the latent reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir. (ClinicalTrials.gov identifier: NCT00051831 .).
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts 02114, USA. rgandhi@partners.org
authors.forename: Rajesh T
authors.initials: RT
authors.lastname: Gandhi
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.forename: Evgenia
authors.initials: E
authors.lastname: Aga
authors.forename: Mary
authors.initials: M
authors.lastname: Albrecht
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Demeter
authors.forename: Carrie
authors.initials: C
authors.lastname: Dykes
authors.forename: Barbara
authors.initials: B
authors.lastname: Bastow
authors.forename: Michael
authors.initials: M
authors.lastname: Para
authors.forename: Jun
authors.initials: J
authors.lastname: Lai
authors.forename: Robert F
authors.initials: RF
authors.lastname: Siliciano
authors.forename: Janet D
authors.initials: JD
authors.lastname: Siliciano
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Eron
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000821:virology*; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D019562:Viral Load; D017735:Virus Latency / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide